vs

Side-by-side financial comparison of LANTRONIX INC (LTRX) and X4 Pharmaceuticals, Inc (XFOR). Click either name above to swap in a different company.

LANTRONIX INC is the larger business by last-quarter revenue ($29.8M vs $28.8M, roughly 1.0× X4 Pharmaceuticals, Inc). X4 Pharmaceuticals, Inc runs the higher net margin — 1.0% vs -4.5%, a 5.4% gap on every dollar of revenue.

Lantronix Inc is a global provider of secure IoT connectivity and edge computing solutions. It offers specialized hardware, SaaS platforms and embedded software for industrial, healthcare, retail, transportation and smart city clients worldwide, supporting reliable remote device management.

X4 Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for rare immunological diseases and oncology indications with high unmet medical needs. It operates primarily across the U.S. and European markets, with a lead pipeline candidate for WHIM syndrome and multiple other preclinical and clinical assets for immune disorders and cancer.

LTRX vs XFOR — Head-to-Head

Bigger by revenue
LTRX
LTRX
1.0× larger
LTRX
$29.8M
$28.8M
XFOR
Higher net margin
XFOR
XFOR
5.4% more per $
XFOR
1.0%
-4.5%
LTRX

Income Statement — Q2 FY2026 vs Q1 FY2025

Metric
LTRX
LTRX
XFOR
XFOR
Revenue
$29.8M
$28.8M
Net Profit
$-1.3M
$282.0K
Gross Margin
43.6%
83.6%
Operating Margin
-3.6%
-32.8%
Net Margin
-4.5%
1.0%
Revenue YoY
-4.5%
Net Profit YoY
43.9%
100.5%
EPS (diluted)
$-0.03
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LTRX
LTRX
XFOR
XFOR
Q4 25
$29.8M
Q3 25
$29.8M
Q2 25
$28.8M
Q1 25
$28.5M
$28.8M
Q4 24
$31.2M
Q3 24
$34.4M
Q2 24
$49.1M
Q1 24
$41.2M
$0
Net Profit
LTRX
LTRX
XFOR
XFOR
Q4 25
$-1.3M
Q3 25
$-1.4M
Q2 25
$-2.6M
Q1 25
$-3.9M
$282.0K
Q4 24
$-2.4M
Q3 24
$-2.5M
Q2 24
$386.0K
Q1 24
$-423.0K
$-51.8M
Gross Margin
LTRX
LTRX
XFOR
XFOR
Q4 25
43.6%
Q3 25
44.8%
Q2 25
40.0%
Q1 25
43.5%
83.6%
Q4 24
42.6%
Q3 24
42.1%
Q2 24
38.1%
Q1 24
40.1%
Operating Margin
LTRX
LTRX
XFOR
XFOR
Q4 25
-3.6%
Q3 25
-5.1%
Q2 25
-10.9%
Q1 25
-12.6%
-32.8%
Q4 24
-6.9%
Q3 24
-6.2%
Q2 24
1.2%
Q1 24
-0.2%
Net Margin
LTRX
LTRX
XFOR
XFOR
Q4 25
-4.5%
Q3 25
-4.7%
Q2 25
-9.1%
Q1 25
-13.6%
1.0%
Q4 24
-7.6%
Q3 24
-7.3%
Q2 24
0.8%
Q1 24
-1.0%
EPS (diluted)
LTRX
LTRX
XFOR
XFOR
Q4 25
$-0.03
Q3 25
$-0.04
Q2 25
$-0.06
Q1 25
$-0.10
$0.04
Q4 24
$-0.06
Q3 24
$-0.07
Q2 24
$0.01
Q1 24
$-0.01
$-7.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LTRX
LTRX
XFOR
XFOR
Cash + ST InvestmentsLiquidity on hand
$23.0M
$40.3M
Total DebtLower is stronger
$75.0M
Stockholders' EquityBook value
$74.4M
$22.9M
Total Assets
$121.7M
$130.0M
Debt / EquityLower = less leverage
3.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LTRX
LTRX
XFOR
XFOR
Q4 25
$23.0M
Q3 25
$22.2M
Q2 25
$20.1M
Q1 25
$20.0M
$40.3M
Q4 24
$19.2M
Q3 24
$26.4M
Q2 24
$26.2M
Q1 24
$24.6M
$60.5M
Total Debt
LTRX
LTRX
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
$75.0M
Q4 24
Q3 24
Q2 24
Q1 24
$55.0M
Stockholders' Equity
LTRX
LTRX
XFOR
XFOR
Q4 25
$74.4M
Q3 25
$74.5M
Q2 25
$74.4M
Q1 25
$75.5M
$22.9M
Q4 24
$77.9M
Q3 24
$78.9M
Q2 24
$81.4M
Q1 24
$78.1M
$1.0M
Total Assets
LTRX
LTRX
XFOR
XFOR
Q4 25
$121.7M
Q3 25
$119.6M
Q2 25
$123.7M
Q1 25
$124.2M
$130.0M
Q4 24
$134.2M
Q3 24
$137.9M
Q2 24
$136.2M
Q1 24
$147.4M
$112.2M
Debt / Equity
LTRX
LTRX
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
3.27×
Q4 24
Q3 24
Q2 24
Q1 24
53.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LTRX
LTRX
XFOR
XFOR
Operating Cash FlowLast quarter
$2.2M
$-12.4M
Free Cash FlowOCF − Capex
$2.1M
FCF MarginFCF / Revenue
7.0%
Capex IntensityCapex / Revenue
0.3%
0.0%
Cash ConversionOCF / Net Profit
-43.86×
TTM Free Cash FlowTrailing 4 quarters
$9.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LTRX
LTRX
XFOR
XFOR
Q4 25
$2.2M
Q3 25
$3.6M
Q2 25
$1.1M
Q1 25
$3.2M
$-12.4M
Q4 24
$340.0K
Q3 24
$2.7M
Q2 24
$2.3M
Q1 24
$3.6M
$-33.6M
Free Cash Flow
LTRX
LTRX
XFOR
XFOR
Q4 25
$2.1M
Q3 25
$3.5M
Q2 25
$909.0K
Q1 25
$3.1M
Q4 24
$256.0K
Q3 24
$2.5M
Q2 24
$2.1M
Q1 24
$3.5M
$-33.7M
FCF Margin
LTRX
LTRX
XFOR
XFOR
Q4 25
7.0%
Q3 25
11.9%
Q2 25
3.2%
Q1 25
10.9%
Q4 24
0.8%
Q3 24
7.3%
Q2 24
4.3%
Q1 24
8.4%
Capex Intensity
LTRX
LTRX
XFOR
XFOR
Q4 25
0.3%
Q3 25
0.2%
Q2 25
0.5%
Q1 25
0.4%
0.0%
Q4 24
0.3%
Q3 24
0.5%
Q2 24
0.3%
Q1 24
0.3%
Cash Conversion
LTRX
LTRX
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
-43.86×
Q4 24
Q3 24
Q2 24
5.89×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LTRX
LTRX

Embedded Io T Solutions$13.9M47%
Io T System Solutions$13.3M45%
Software And Services$2.6M9%

XFOR
XFOR

Segment breakdown not available.

Related Comparisons